Coronary Artery Disease in Diabetes

  • Doron Aronson
  • Michael T. Johnstone
Part of the Contemporary Cardiology book series (CONCARD)


Both insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) are powerful and independent risk factors for coronary artery disease (CAD), stroke, and peripheral arterial disease (1–3). Furthermore, when patients with diabetes develop clinical events, they sustain a worse prognosis compared with nondiabetics (4). Ultimately, atherosclerosis accounts for 65–80% of all deaths among North American diabetic patients, compared with one-third of all deaths in the general North American population (3, 5, 6). A two- to fourfold excess in CAD mortality among diabetic individuals has been noted in a number of prospective studies encompassing a variety of ethnic and racial groups (7). Diabetes also increases the likelihood of severe carotid atherosclerosis (8,9) and mortality from stroke is increased almost threefold in diabetic patients (1).


Diabetic Patient Acute Myocardial Infarction Diabetic Nephropathy Autonomic Neuropathy Nondiabetic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16: 434–444.PubMedCrossRefGoogle Scholar
  2. 2.
    Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992;15:1156–1167.PubMedCrossRefGoogle Scholar
  3. 3.
    Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134–1146.PubMedCrossRefGoogle Scholar
  4. 4.
    Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997;126:296–306.PubMedCrossRefGoogle Scholar
  5. 5.
    Barrett-Connor E, Orchard T. Diabetes and heart disease. National Diabetes Data Group, Diabetes Data Compiled 1984. NIH Publication no. 85–1468. US Department of Health and Human Services, Washington, DC, 1985, pp. XVI-1-XVI-41.Google Scholar
  6. 6.
    AmericanDiabetesAssociation.Consensusstatement:roleofcardiovascularriskfactorsinprevention and treatment of macrovascular disease in diabetes. Diabetes Care 1993;16:72–78.Google Scholar
  7. 7.
    Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463–524.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Leary D, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992;23:1752–1760.PubMedCrossRefGoogle Scholar
  9. 9.
    Folsom AR, Eckfeldt JH, Weitzman S, et al. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994;25:66–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Edelman SV. Type II diabetes mellitus. Adv Intern Med 1998;43:449–500.PubMedGoogle Scholar
  11. 11.
    Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996;125:221232.Google Scholar
  12. 12.
    Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750–755.PubMedCrossRefGoogle Scholar
  13. 13.
    Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care 1992;15:1141–1155.PubMedCrossRefGoogle Scholar
  14. 14.
    Maser RE, Wolfson SK Jr, Ellis D, et al. Cardiovascular disease and arterial calcification in insulindependent diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study V. Arterioscler Thromb 1991;11:958–965.PubMedCrossRefGoogle Scholar
  15. 15.
    Earle K, Viberti GC. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int 1994;45:434–437.PubMedCrossRefGoogle Scholar
  16. 16.
    Borch-Johnsen K, Norgaard K, Hommel E, et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992;41:719–722.PubMedCrossRefGoogle Scholar
  17. 17.
    Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987;30:144–148.PubMedCrossRefGoogle Scholar
  18. 18.
    Manske CL, Wilson RF, Wang Y, Thomas W. Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy. Arch Intern Med 1992; 152:2450–2455.PubMedCrossRefGoogle Scholar
  19. 19.
    Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 1992;15:1181–1191.PubMedCrossRefGoogle Scholar
  20. 20.
    Jensen T, Stender S, Deckert T. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988;31:142–145.PubMedCrossRefGoogle Scholar
  21. 21.
    Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC. Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 1989;298:487–490.PubMedCrossRefGoogle Scholar
  22. 22.
    Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Mackness M, Arrol S. Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition. Atherosclerosis 1991;89:49–57.PubMedCrossRefGoogle Scholar
  23. 23.
    Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 1994;43:426–429.PubMedCrossRefGoogle Scholar
  24. 24.
    Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519–1522.PubMedCrossRefGoogle Scholar
  25. 25.
    Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836–842.PubMedCrossRefGoogle Scholar
  26. 26.
    Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161–1165.PubMedCrossRefGoogle Scholar
  27. 27.
    Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997;99:1585–1595.PubMedCrossRefGoogle Scholar
  28. 28.
    Earle K, Walker J, Hill C, Viberti G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992;326:673–677.PubMedCrossRefGoogle Scholar
  29. 29.
    Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988;318:140–145.PubMedCrossRefGoogle Scholar
  30. 30.
    Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641–644.PubMedCrossRefGoogle Scholar
  31. 31.
    Tarnow L, Cambien F, Rossing P, et al. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 1995;38:798–803.PubMedCrossRefGoogle Scholar
  32. 32.
    Ruiz J, Blanche H, Cohen N, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994;91:3662–3665.PubMedCrossRefGoogle Scholar
  33. 33.
    Keavney BD, Dudley CR, Stratton IM, et al. UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infraction in MDDM. Diabetologia 1995;38:948–952.PubMedCrossRefGoogle Scholar
  34. 34.
    Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120–126.PubMedCrossRefGoogle Scholar
  35. 35.
    Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982;22:79–84.PubMedGoogle Scholar
  36. 36.
    Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease putative association via common antecedents;further evidence from the Whitehall Study. Diabetologia 1988;31:737–740.PubMedCrossRefGoogle Scholar
  37. 37.
    Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subj ects with impa ired glucose tolera nce or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300–304.PubMedCrossRefGoogle Scholar
  38. 38.
    Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265:627–631.PubMedCrossRefGoogle Scholar
  39. 39.
    Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676–1685.PubMedCrossRefGoogle Scholar
  40. 40.
    Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 1983;118:489–496.PubMedGoogle Scholar
  41. 41.
    Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350–357.PubMedCrossRefGoogle Scholar
  42. 42.
    Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702–706.PubMedCrossRefGoogle Scholar
  43. 43.
    Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ (Clin Res Ed) 1984;288:1401–1404.CrossRefGoogle Scholar
  44. 44.
    Laakso M, Barrett-Connor E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 1989;9:665–672.PubMedCrossRefGoogle Scholar
  45. 45.
    Laws A, King AC, Haskell WL, Reaven GM. Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride concentrations in men. Arterioscler Thromb 1991;11: 1636–1642.PubMedCrossRefGoogle Scholar
  46. 46.
    Modan M, Halkin H, Lusky A, Segal P, Fuchs Z, Chetrit A. Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL, and HDL levels. A population-based study. Arteriosclerosis 1988;8:227–236.PubMedCrossRefGoogle Scholar
  47. 47.
    Peiris AN, Sothmann MS, Hoffmann RG, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989;110:867–872.PubMedCrossRefGoogle Scholar
  48. 48.
    Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121–131.PubMedCrossRefGoogle Scholar
  49. 49.
    Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 1994;37:948–952.PubMedCrossRefGoogle Scholar
  50. 50.
    Howard G, O’Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809–1817.PubMedCrossRefGoogle Scholar
  51. 51.
    Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991;11:1068–1076.PubMedCrossRefGoogle Scholar
  52. 52.
    Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995;26:956–960.PubMedCrossRefGoogle Scholar
  53. 53.
    Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980;1:1373–1376.PubMedCrossRefGoogle Scholar
  54. 54.
    Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates. Diabetologia 1990;33:538–541.PubMedCrossRefGoogle Scholar
  55. 55.
    Uusitupa M, Siitonen O, Pyorala K, et al. The relationship of cardiovascular risk factors to the prevalence of coronary heart disease in newly diagnosed type 2 (non-insulin-dependent) diabetes. Diabetologia 1985;28:653–659.PubMedCrossRefGoogle Scholar
  56. 56.
    Head J, Fuller JH. International variations in mortality among diabetic patients: the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1990;33:477–481.PubMedCrossRefGoogle Scholar
  57. 57.
    Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC. Association of HbAlc with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992;41:202–208.PubMedCrossRefGoogle Scholar
  58. 58.
    Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960–967.PubMedCrossRefGoogle Scholar
  59. 59.
    Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736–741.PubMedCrossRefGoogle Scholar
  60. 60.
    Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993;16:996–1003.PubMedCrossRefGoogle Scholar
  61. 60a.
    Geerlings W, Tufveson G, Brunner FP, et al. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrol Dial Transplant 1991;6(Supp14):5−29.Google Scholar
  62. 60.
    b. Renal failure in diabetics in the UK: deficient provision of care in 1985. Joint Working Party on Diabetic Renal Failure of the British Diabetic Association, the Renal Association, and the Research Unit of the Royal College of Physicians. Diabetes Med 1988;5:79–84.Google Scholar
  63. 60c.
    Lemmers MJ, Barry JM. Major role for arterial disease in morbidity and mortality after kidney transplantation in diabetic recipients. Diabetes Care 1991;14:295–301.PubMedCrossRefGoogle Scholar
  64. 61.
    Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 1991;14:839–855.CrossRefGoogle Scholar
  65. 62.
    Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:160–178.PubMedCrossRefGoogle Scholar
  66. 63.
    Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993;88:381–387.PubMedCrossRefGoogle Scholar
  67. 64.
    Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993;19:122–128.PubMedCrossRefGoogle Scholar
  68. 65.
    Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995;21:152–160.PubMedCrossRefGoogle Scholar
  69. 66.
    Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672–676.PubMedCrossRefGoogle Scholar
  70. 67.
    Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1–7.PubMedCrossRefGoogle Scholar
  71. 68.
    Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential riskfactor for vascular disease. Circulation 1994;89:321–330.PubMedCrossRefGoogle Scholar
  72. 69.
    Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated va sodila tion in pa tients with non-insulin-dependent diabetes mellitus. J Am Coll Cardio11996;27:567–574.Google Scholar
  73. 70.
    Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endotheliumdependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510–2516.PubMedCrossRefGoogle Scholar
  74. 71.
    Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–1321.PubMedCrossRefGoogle Scholar
  75. 72.
    Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138–151.PubMedGoogle Scholar
  76. 73.
    Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143: 1649–1656.PubMedGoogle Scholar
  77. 74.
    Higashi T, Sano H, Saishoji T, et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 1997;46:463–472.PubMedCrossRefGoogle Scholar
  78. 75.
    Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010–9014.PubMedCrossRefGoogle Scholar
  79. 76.
    Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor Iinhuman monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992;90: 439–446.PubMedCrossRefGoogle Scholar
  80. 77.
    Vigorita VJ, Moore GW, Hutchins GM. Absence of correlation between coronary arterial atherosclerosis and severity or duration of diabetes mellitus of adult onset. Am J Cardiol 1980;46:535–542.PubMedCrossRefGoogle Scholar
  81. 78.
    Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980;69:498–506.PubMedCrossRefGoogle Scholar
  82. 79.
    Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920–925.PubMedCrossRefGoogle Scholar
  83. 80.
    Stein B, Weintraub W, Gebhart S, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979–989.PubMedCrossRefGoogle Scholar
  84. 81.
    Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). Am J Cardiol 1994;74:334–339.PubMedCrossRefGoogle Scholar
  85. 82.
    Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989;10:203–208.PubMedGoogle Scholar
  86. 83.
    Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995;92:1731–1736.PubMedCrossRefGoogle Scholar
  87. 83a.
    Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180–2184.PubMedCrossRefGoogle Scholar
  88. 84.
    Bradley RF, Schonfeld A. Diminished pain in diabetic patients with acute myocardial infarction. Geriatrics 1962;17:322–326.PubMedGoogle Scholar
  89. 85.
    Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction-silent and asymptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 1973;32:1–7.PubMedCrossRefGoogle Scholar
  90. 86.
    Soler NG, Bennett MA, Pentecost BL, Fitzgerald MG, Malins JM. Myocardial infarction in diabetics. Q J Med 1975;44:125–132.PubMedGoogle Scholar
  91. 87.
    Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardio11993;22:1433–1437.Google Scholar
  92. 88.
    Hume L, Oakley GD, Boulton AJ, Hardisty C, Ward JD. Asymptomatic myocardial ischemia in diabetes and its relationship to diabetic neuropathy: an exercise electrocardiography study in middle-aged diabetic men. Diabetes Care 1986;9:384–388.PubMedCrossRefGoogle Scholar
  93. 89.
    O’Sullivan J, Conroy RM, MacDonald K, McKenna TJ, Maurer BJ. Silent ischaemia in diabetic men with autonomic neuropathy. Br Heart J 1991;66:313–315.PubMedCrossRefGoogle Scholar
  94. 90.
    Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med;1988;108:170–175.PubMedCrossRefGoogle Scholar
  95. 91.
    Abenavoli T, Rubler S, Fisher VJ, Axelrod HI, Zuckerman KP. Exercise testing with myocardial scintigraphy in asymptomatic diabetic males. Circulation 1981;63:54–64.PubMedCrossRefGoogle Scholar
  96. 92.
    Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991;67:1073–1078.PubMedCrossRefGoogle Scholar
  97. 93.
    Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997;79:134–139.CrossRefGoogle Scholar
  98. 94.
    Callaham PR, Froelicher VF, Klein J, Risch M, Dubach P, Friis R. Exercise-induced silent ischemia: age, diabetes mellitus, previous myocardial infarction and prognosis. J Am Coll Cardiol 1989;14: 1175–1180.PubMedCrossRefGoogle Scholar
  99. 95.
    Caracciolo EA, Chaitman BR, Forman SA, et al. Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators. Circulation 1996;93:2097–2105.PubMedCrossRefGoogle Scholar
  100. 96.
    Faerman I, Faccio E, Milei J, et al. Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes 1977;26:1147–1158.PubMedCrossRefGoogle Scholar
  101. 97.
    Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990;15:72–77.PubMedCrossRefGoogle Scholar
  102. 98.
    Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108:31–37.PubMedCrossRefGoogle Scholar
  103. 99.
    Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988;62:665–669.PubMedCrossRefGoogle Scholar
  104. 100.
    Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9: 259–264.PubMedGoogle Scholar
  105. 101.
    Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989; 14:49–57.PubMedCrossRefGoogle Scholar
  106. 102.
    Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:171–179.PubMedCrossRefGoogle Scholar
  107. 103.
    Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1993;22:707–713.PubMedCrossRefGoogle Scholar
  108. 104.
    Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659–1668.PubMedCrossRefGoogle Scholar
  109. 105.
    Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788–1794.PubMedCrossRefGoogle Scholar
  110. 106.
    Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999;100:2067–2073.PubMedCrossRefGoogle Scholar
  111. 107.
    Orlander PR, Goff DC, Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes 1994;43:897–902.PubMedCrossRefGoogle Scholar
  112. 108.
    Lehto S, Pyorala K, Miettinen H, et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med 1994;236:291–297.PubMedCrossRefGoogle Scholar
  113. 109.
    Ulvenstam G, Aberg A, Bergstrand R, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985;34:787–792.PubMedCrossRefGoogle Scholar
  114. 110.
    Iwasaka T, Takahashi N, Nakamura S, et al. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care 1992;15:1522–1526.PubMedCrossRefGoogle Scholar
  115. 111.
    Fava S, Azzopardi J, Muscat HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 1993;16:1615–1618.PubMedCrossRefGoogle Scholar
  116. 112.
    Gwilt DJ, Petri M, Lewis PW, Nattrass M, Pentecost BL. Myocardial infarct size and mortality in diabetic patients. Br Heart J 1985;54:466–472.PubMedCrossRefGoogle Scholar
  117. 113.
    Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988;12: 114–120.PubMedCrossRefGoogle Scholar
  118. 114.
    Takahashi N, Iwasaka T, Sugiura T, et al. Left ventricular regional function after acute anterior myocardial infarction in diabetic patients. Diabetes Care 1989;12:630–635.PubMedCrossRefGoogle Scholar
  119. 115.
    The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–1622.Google Scholar
  120. 116.
    Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239–2242.PubMedCrossRefGoogle Scholar
  121. 117.
    Capone RJ, Pawitan Y, el-Sherif N, et al. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol 1991;18:1434–1438.PubMedCrossRefGoogle Scholar
  122. 118.
    Herlitz J, Malmberg K, Karlson BW, Ryden L, Hjalmarson A. Mortality and morbidity during a fiveyear follow-up of diabetics with myocardial infarction. Acta Med Scand 1988;224:31–38.PubMedCrossRefGoogle Scholar
  123. 119.
    Gilpin E, Ricou F, Dittrich H, Nicod P, Henning H, Ross J Jr. Factors associated with recurrent myocardial infarction within one year after acute myocardial infarction. Am Heart J 1991;121:457–465.PubMedCrossRefGoogle Scholar
  124. 120.
    Taylor GJ, Moses HW, Katholi RE, et al. Six-year survival after coronary thrombolysis and early revascularization for acute myocardial infarction. Am J Cardiol 1992;70:26–30.PubMedCrossRefGoogle Scholar
  125. 121.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334: 1383–1389.Google Scholar
  126. 122.
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–620.PubMedCrossRefGoogle Scholar
  127. 123.
    Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446–1452.PubMedCrossRefGoogle Scholar
  128. 124.
    Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434–6438.PubMedCrossRefGoogle Scholar
  129. 125.
    Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993; 71:26B–31B.CrossRefGoogle Scholar
  130. 126.
    Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141–146.PubMedCrossRefGoogle Scholar
  131. 127.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234.PubMedCrossRefGoogle Scholar
  132. 127a.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513–2519.PubMedCrossRefGoogle Scholar
  133. 127.
    b.Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661–2667.Google Scholar
  134. 127c.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–418.PubMedCrossRefGoogle Scholar
  135. 128.
    The Sixth Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413–2446.CrossRefGoogle Scholar
  136. 128a.
    National High Blood Pressure Education Program Working Group Report on Hypertension and Diabetes. Hypertension 1994;23:145–158.CrossRefGoogle Scholar
  137. 129.
    b.American Diabetes Association. Consensus statement on the treatment of hypertension in diabetes. Diabetes Care 1993;16:1394–1401.Google Scholar
  138. 129.
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645–652.PubMedCrossRefGoogle Scholar
  139. 130.
    Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597–603.PubMedCrossRefGoogle Scholar
  140. 131.
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group [published erratum appears in JAMA 1997; 277:1356]. JAMA 1996;276:1886–1892.PubMedCrossRefGoogle Scholar
  141. 132.
    Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998;351: 689–690.PubMedCrossRefGoogle Scholar
  142. 133.
    Sowers JR. Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). Am J Cardiol 1998;82:15R–19R.CrossRefGoogle Scholar
  143. 134.
    Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340:677–684.PubMedCrossRefGoogle Scholar
  144. 135.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–1762.PubMedCrossRefGoogle Scholar
  145. 136.
    Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213–219.PubMedCrossRefGoogle Scholar
  146. 137.
    Parving HH. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998;41:745–759.PubMedCrossRefGoogle Scholar
  147. 138.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.CrossRefGoogle Scholar
  148. 139.
    The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894–903.CrossRefGoogle Scholar
  149. 140.
    Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97:1767–1773.PubMedCrossRefGoogle Scholar
  150. 141.
    Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LE, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996;45: 1253–1258.PubMedCrossRefGoogle Scholar
  151. 142.
    UKProspectiveDiabetesStudy(UKPDS)Group.Intensiveblood-glucosecontrolwithsulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.CrossRefGoogle Scholar
  152. 143.
    The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289–1298.CrossRefGoogle Scholar
  153. 144.
    Klein R, Klein BE, Moss SE, Shrago ES, Spennetta TL. Glycosylated hemoglobin in a populationbased study of diabetes. Am J Epidemiol 1987;126:415–428.PubMedGoogle Scholar
  154. 145.
    ADA Consensus statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18:1510–1518.Google Scholar
  155. 146.
    Clark RS, English M, McNeill GP, Newton RW. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. BMJ (Clin Res Ed) 1985;291:303–305.CrossRefGoogle Scholar
  156. 147.
    Gwilt DJ, Petri M, Lamb P, Nattrass M, Pentecost BL. Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction. Br Heart J 1984;51:626–630.PubMedCrossRefGoogle Scholar
  157. 148.
    Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57–65.PubMedCrossRefGoogle Scholar
  158. 149.
    Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512–1515.PubMedCrossRefGoogle Scholar
  159. 150.
    Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626–2632.PubMedCrossRefGoogle Scholar
  160. 150a.
    American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 1998;21:1551–1559.CrossRefGoogle Scholar
  161. 151.
    Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769–1774.PubMedCrossRefGoogle Scholar
  162. 152.
    DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986;68:886–891.PubMedGoogle Scholar
  163. 153.
    Randomized trial of intravenous streptokinase OA, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349–360.Google Scholar
  164. 154.
    Antiplatelet Trialist’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.CrossRefGoogle Scholar
  165. 155.
    Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997;20:1767–1771.PubMedGoogle Scholar
  166. 156.
    American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 1997;20:1772–1773.Google Scholar
  167. 157.
    Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995;123:358–367.PubMedCrossRefGoogle Scholar
  168. 158.
    Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285–290.PubMedCrossRefGoogle Scholar
  169. 159.
    Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989;10:423–428.PubMedGoogle Scholar
  170. 160.
    Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43–50.PubMedGoogle Scholar
  171. 161.
    Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol 1999;34:1388–1394.PubMedCrossRefGoogle Scholar
  172. 162.
    Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713–1720.PubMedCrossRefGoogle Scholar
  173. 163.
    Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278:40–43.PubMedCrossRefGoogle Scholar
  174. 164.
    Pfeffer MA. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation 1998;97:2192–2194.PubMedCrossRefGoogle Scholar
  175. 165.
    Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96:4239–4245.PubMedCrossRefGoogle Scholar
  176. 166.
    Moye LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994;15(Suppl B):2–8; discussion 26–30.Google Scholar
  177. 167.
    Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999;34: 83–89.PubMedCrossRefGoogle Scholar
  178. 168.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effect of angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145–153.CrossRefGoogle Scholar
  179. 168a.
    Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and the MICRO-HOPE Study. Lancet 2000;350:253–259.Google Scholar
  180. 169.
    Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868–873.PubMedCrossRefGoogle Scholar
  181. 170.
    Torlone E, Rambotti AM, Perriello G, et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991;34:119–125.PubMedCrossRefGoogle Scholar
  182. 171.
    Bak JF, Gerdes LU, Sorensen NS, Pedersen O. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 1992;92: 69S–72S.CrossRefGoogle Scholar
  183. 172.
    LewisEJ,HunsickerLG,BainRP,RohdeRD.Theeffectofangiotensin-converting-enzymeinhibition on diabetic nephropathy. The Collaborative Study Group [published erratum appears in N Engl J Med 1993;330:152]. N Engl J Med 1993;329:1456–1462.Google Scholar
  184. 173.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensinconverting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–581.PubMedCrossRefGoogle Scholar
  185. 173a.
    PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med 1998; 338:1488–1497.CrossRefGoogle Scholar
  186. 174.
    Steinbuhl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999;100:1977–1982.CrossRefGoogle Scholar
  187. 175.
    TheEPILOGInvestigators.PlateletglycoproteinIIb/IIIareceptorblockadeandlow-doseheparinduring percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696.CrossRefGoogle Scholar
  188. 176.
    Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996;28:1661–1669.PubMedCrossRefGoogle Scholar
  189. 177.
    Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311–322.Google Scholar
  190. 178.
    Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic. J Am Coll Cardiol 1997;30:1606–1610.PubMedCrossRefGoogle Scholar
  191. 179.
    Detre K, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988;318: 265–270.PubMedCrossRefGoogle Scholar
  192. 180.
    Adelman A, Cohen E, Kimball B, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. N Engl J Med. 1993;329:228–233.PubMedCrossRefGoogle Scholar
  193. 181.
    Parisi A, Folland E, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1993;326:10–16.CrossRefGoogle Scholar
  194. 182.
    The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335: 217–225.CrossRefGoogle Scholar
  195. 183.
    Holmes DJ, Vietstra R, Smith H, et al. Restenosis after percutanous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77C–81C.CrossRefGoogle Scholar
  196. 184.
    Weintraub W, Kosinski A, Brown C, King S. Can restenosis after coronary angioplasty be predicted from clinical variables. J Am Coll Cardiol 1993;21:6–14.PubMedCrossRefGoogle Scholar
  197. 185.
    Vandormael MG, Deligonul U, Kern MJ, et al. Multilesion coronary angioplasty: clinical and angiographic follow-up. J Am Coll Cardiol 1987;10:246–252.PubMedCrossRefGoogle Scholar
  198. 186.
    Quigley PJ, Hlatky MA, Hinohara T, et al. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. Am J Cardiol 1989;63:409–413.Google Scholar
  199. 187.
    Rensing BJ, Hermans WR, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation 1993;88:975–985.PubMedCrossRefGoogle Scholar
  200. 188.
    Bach R, Jung F, Kohsiek I, et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. Thromb Hemost 1994;74:(Suppl 1):S55–S77.Google Scholar
  201. 189.
    Lambert M, Bonan R, Cote G, et al. Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis. J Am Coll Cardiol 1988;12:310–314.PubMedCrossRefGoogle Scholar
  202. 190.
    Popma JJ, Mintz GS, Satler LF, et al. Clinical and angiographic outcome after directional coronary atherectomy. A qualitative and quantitative analysis using coronary arteriography and intravascular ultrasound. Am J Cardiol 1993;72:55E–64E.CrossRefGoogle Scholar
  203. 191.
    Warth D, LeonMB, O’Neill W, ZaccaN, PolissarN, BuchbinderM. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994;24:641–648.PubMedCrossRefGoogle Scholar
  204. 192.
    Levine GN, Jacobs AK, Keeler GP, et al. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty versus Excisional Atherectomy Trial. Am J Cardiol 1997;79:748–755.PubMedCrossRefGoogle Scholar
  205. 193.
    Rabbani L, Edelman E, Ganz P, Selwyn A, Loscalzo J, Bitti J. Relation of restenosis after excimer laser angioplasty to fasting insulin levels. Am J Cardiol 1994;73:323–327.PubMedCrossRefGoogle Scholar
  206. 194.
    Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496–501.PubMedCrossRefGoogle Scholar
  207. 195.
    Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428–1436.PubMedCrossRefGoogle Scholar
  208. 196.
    Kastrati A, Schomig A, Elezi S, Schuhlen H, Wilhelm M, Dirschinger J. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. Circulation 1998; 97:2396–2401.PubMedCrossRefGoogle Scholar
  209. 197.
    Carrozza J, Kuntz R, Fishman R, Baim D. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344–349.PubMedCrossRefGoogle Scholar
  210. 198.
    Wang N, Gundry SR, Van Arsdell G, et al. Percutaneous transluminal coronary angioplasty failures in patients with multivessel disease. Is there an increased risk? J Thorac Cardiovasc Surg 1995;110:214–221; discussion 221–223.Google Scholar
  211. 199.
    Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997;96:1454–1460.PubMedCrossRefGoogle Scholar
  212. 199a.
    Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 1999;99:2496–2498.CrossRefGoogle Scholar
  213. 199.
    b.Sobe1 BE. Acceleration of restenosis by diabetes. Circulation 2001;103:1185–1187.CrossRefGoogle Scholar
  214. 200.
    Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818–1825.PubMedCrossRefGoogle Scholar
  215. 201.
    Gum P, O’Keefe JJ, Borkon A, et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 1997;96 (9 Suppl):II7–II10.Google Scholar
  216. 202.
    Ellis CJ, French JK, White HD, Ormiston JA, Whitlock RM, Webster MW. Results of percutaneous coronary angioplasty in patients <40 years of age. Am J Cardiol 1998;82:135–139.PubMedCrossRefGoogle Scholar
  217. 203.
    Dauerman HL, Baim DS, Cutlip DE, et al. Mechanical debulling versus balloon angioplasty for the treatment of diffuse in-stent restenosis. Am J Cardiol 1998;82:277–284.PubMedCrossRefGoogle Scholar
  218. 203a.
    Van Belle E, Ketelers R, Bauters C, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001;103:1218–1224.PubMedCrossRefGoogle Scholar
  219. 204.
    Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPIS TENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 1999;100:2477–2484.PubMedCrossRefGoogle Scholar
  220. 205.
    Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366–1369.PubMedCrossRefGoogle Scholar
  221. 206.
    Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528–535.PubMedCrossRefGoogle Scholar
  222. 207.
    Fietsam R Jr, Bassett J, Glover JL. Complications of coronary artery surgery in diabetic patients. Am Surg 1991;57:551–557.PubMedGoogle Scholar
  223. 208.
    Slaughter MS, Olson MM, Lee JT Jr, Ward HB. A fifteen-year wound surveillance study after coronary artery bypass. Ann Thorac Surg 1993;56:1063–1068.PubMedCrossRefGoogle Scholar
  224. 209.
    Palac RT, Meadows WR, Hwang MH, Loeb HS, Pifarre R, Gunnar RM. Risk factors related to progressive narrowing in aortocoronary vein grafts studied 1 and 5 years after surgery. Circulation 1982; 66:140–144.Google Scholar
  225. 210.
    Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248–258.PubMedGoogle Scholar
  226. 211.
    Hirotani T, Kameda T, Kumamoto T, Shirota S, Yamano M. Effects of coronary artery bypass grafting using internal mammary arteries for diabetic patients. J Am Coll Cardiol 1999;34:532–538.PubMedCrossRefGoogle Scholar
  227. 212.
    Davies M, Kim J, Klyachkin M, et al. Diabetes mellitus and experimental vein graft structure and function. J Vasc Surg 1994;19:1031–1043.PubMedCrossRefGoogle Scholar
  228. 213.
    Morris JJ, Smith LR, Jones RH, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991;84:III275–III284.Google Scholar
  229. 214.
    Herlitz J, Bang A, Karlson BW. Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology 1996; 87:423–428.PubMedCrossRefGoogle Scholar
  230. 215.
    Lawrie GM, Morris GC Jr, Glaeser DH. Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up of 212 diabetic patients ten to 15 years after surgery. JAMA 1986;256:2967–2971.PubMedCrossRefGoogle Scholar
  231. 216.
    The Bypass Angioplasty Revascularization Investigation (BARI). Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997;96:1761–1769.CrossRefGoogle Scholar
  232. 217.
    Ferguson J. NHLBI BARI clinical alert on diabetics treated with angioplasty. Circulation 1995;92: 3371.PubMedCrossRefGoogle Scholar
  233. 218.
    Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551–2556.PubMedCrossRefGoogle Scholar
  234. 219.
    Weintraub W, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998;31: 10–19.PubMedCrossRefGoogle Scholar
  235. 220.
    Zhao X, Brown B, Stewart D, et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. Circulation 1996; 93:1954–1962.PubMedCrossRefGoogle Scholar
  236. 221.
    BellMR,GershBJ,SchaffHV,etal.Effectofcompletenessofrevascularizationonlong-termoutcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Circulation 1992;86:446–457.CrossRefGoogle Scholar
  237. 222.
    Schaff HV, Rosen AD, Shemin RJ, et al. Clinical and operative characteristics of patients randomized to coronary artery bypass surgery in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Cardiol 1995;75:18C–26C.CrossRefGoogle Scholar
  238. 223.
    Nashar P, Brown R, Oskarsson H, Winniford M, Rossen J. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995;91:635–640.CrossRefGoogle Scholar
  239. 224.
    Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992;85:1254–1264.PubMedCrossRefGoogle Scholar
  240. 225.
    Spallone V, Maiello MR, Cicconetti E, et al. Autonomic neuropathy and cardiovascular risk factors in insulin- dependent and non insulin-dependent diabetes. Diabetes Res Clin Pract 1997:34;169–179.PubMedCrossRefGoogle Scholar
  241. 226.
    Toyry JP, Niskanen LK, Mantysaari MJ, et al. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 1996:45;308–315.PubMedCrossRefGoogle Scholar
  242. 227.
    Sampson MJ, Wilson S, Karagiannis P, et al. Progression of diabetic autonomic neuropathy over a decade in insulin- dependent diabetics. Q J Med 1990:75;635–646.PubMedGoogle Scholar
  243. 228.
    O’Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulindependent diabetes. Q J Med 1991:79:495–502.PubMedGoogle Scholar
  244. 229.
    Orchard TJ, Ce LL, Maser RE, et al. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996;34(Suppl):S165–171.CrossRefGoogle Scholar
  245. 230.
    Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989:79:733–743.PubMedCrossRefGoogle Scholar
  246. 231.
    Zarich S, Waxman S, Freeman RT, et al. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 1994 24:956–962.PubMedCrossRefGoogle Scholar
  247. 232.
    Bernardi L, Ricordi L, Lazzari P, et al. Impaired circadian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation 1992: 86:1443–1452.PubMedCrossRefGoogle Scholar
  248. 233.
    Kahn JK, Zola B, Juni JE, Vinik AI. Decreased exercise heart rate and blood pressure response in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 1986;9:389–394.PubMedCrossRefGoogle Scholar
  249. 234.
    Hiltsted J Galbo H, Christensen N. Impaired cardiovascular responses to graded exercise in diabetic autonimic neuropathy. Diabetes 1979;28:313–319.Google Scholar
  250. 235.
    Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 1997;336:1208–1215.PubMedCrossRefGoogle Scholar
  251. 236.
    Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999;100:813–819.PubMedCrossRefGoogle Scholar
  252. 237.
    Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997;46(Suppl) 2:S67–S76.Google Scholar
  253. 238.
    Ziegler, D, Dannehl K, Volksw D, et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart-rate variation in newly diagnosed IDDM patients. Diabetes Care 1992:15:908–911.PubMedCrossRefGoogle Scholar
  254. 239.
    Ewing DJ, Neilson JM, Shapiro CM, Stewart JA, Reid W. Twenty four hour heart rate variability: effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients. Br Heart J 1991;65:239–244.PubMedCrossRefGoogle Scholar
  255. 240.
    Kreiner G, Wolzt M, Fasching P, et al. Myocardial m-[1231]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 1995;44:543–549.PubMedCrossRefGoogle Scholar
  256. 241.
    Kleiger RE, Miller JP, BiggerJ, Moss AJ, for the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardio1.1987;59:256–262.CrossRefGoogle Scholar
  257. 242.
    Farrell TG, Bashir Y, Poloniecki J, Camm J. Risk stratification of arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables, and signal averaged electrocardiogram. J Am Coll Cardiol 1991;18:687–697.PubMedCrossRefGoogle Scholar
  258. 243.
    Bigger JT, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variablity and mortality after myocardial infarction. Circulation 1992;85:164–171.PubMedCrossRefGoogle Scholar
  259. 244.
    Pozzati A, Pancaldi LG, Di Pasquale G, et al. Transient sympathovagal imbalance triggers “ischemic” sudden death in patients undergoing electrocardiographic Holter monitoring. J Am Coll Cardiol 1996; 27:847–852.PubMedCrossRefGoogle Scholar
  260. 245.
    Curb JD, Rodriguez BL, Burchfiel CM, et al. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995;91:2591–2595.PubMedCrossRefGoogle Scholar
  261. 246.
    Kahn JK, Sisson JC, Vinik AI. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy. J Clin Endocrinol Metab 1987;64:751–754.PubMedCrossRefGoogle Scholar
  262. 247.
    Wei K, Dorian P, Newman D, et al. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol 1995;26:859–863.PubMedCrossRefGoogle Scholar
  263. 248.
    Marchant B, Umachandran V, Stevenson R, et al. Silent myocardial ischemia:role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993;22:1433–1437.PubMedCrossRefGoogle Scholar
  264. 249.
    Ambepityia G, Kopelman PG, Ingram D, et al. Exertional myocardial ischemia in diabetes:a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990;15:72–77.PubMedCrossRefGoogle Scholar
  265. 250.
    Faerman I, Faccio E, Milei J, et al. Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes 1977;26:1147–1158.PubMedCrossRefGoogle Scholar
  266. 251.
    Burgos LG, Ebert TJ, Asiddao C, et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989;70:591–597.PubMedCrossRefGoogle Scholar
  267. 252.
    Keyl C, Lemberger P, Palitzsch KD, et al. Cardiovascular autonomic dysfunction and hemodynamic response to anesthetic induction in patients with coronary artery disease and diabetes mellitus. Anesth Analg 1999;88:985–991.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Doron Aronson
  • Michael T. Johnstone

There are no affiliations available

Personalised recommendations